Navigation Links
OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Date:2/15/2008

p> not manifested disease progression and approximately 60 percent of

patients remain alive in both arms. Median survival has not been

reached in either arm. These data compare favorably with published

results documenting median survivals of approximately 10 months.

- Reduction in pain or analgesic use was achieved in 50 percent or more

of patients entering the study with pain: Reductions in pain or

analgesic use were seen in 50 percent of evaluable patients treated

with mitoxantrone and in 67 percent of evaluable patients retreated

with docetaxel. These data compare favorably to the 22-35 percent of

patients receiving first-line chemotherapy who reported reduction in

pain in the TAX 327 study published in the New England Journal of

Medicine on October 7, 2004.

This Phase 2 study was designed as an open-label, randomized, multicenter study evaluating weekly administration of OGX-011 in combination with second-line chemotherapy in patients with metastatic hormone refractory prostate cancer who were previously treated with a minimum of 2 cycles of docetaxel-based first-line chemotherapy. Patients in this study represented a poor prognostic population due to rapid disease progression after completing first-line docetaxel therapy with a median of 0.7 months in the mitoxantrone treated group or 2.1 months in the docetaxel retreated group. Because OGX-011 has been shown to enhance chemotherapy and reverse chemotherapy resistance in preclinical in vitro and in vivo models, the aim of this study was to assess the effect of OGX-011 in combination with either mitoxantrone or docetaxel retreatment as second-line chemotherapy. Phase 3 studies are planned utilizing chemotherapy plus OGX-011 as second-line therapy in patients progressing after a first-line docetaxel regimen.

"These data show that the combination of OGX-011 with docetaxel or mitoxantrone may
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... --  SunTrust Robinson Humphrey (STRH) today announced ... equity research team in biotechnology and oilfield services.  ... research demonstrates our commitment to providing our valued ... investment decision making," said Biff Woodruff , ... make significant investments in differentiated content at a ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
(Date:8/28/2014)... August 27, 2014 Scientists, researchers, and ... SPIE Laser Damage 2014 symposium. Marking its ... high-power lasers will run 14-17 September. The event is ... and photonics . , The premier conference for basic ... damage to optical materials will engage researchers and engineers ...
(Date:8/28/2014)... August 28, 2014 Earlier this month, ... in partnership with the U.S. Air Force on ... The results indicated that this type of fuel made ... and will be important to America’s Eco friendly future. ... has a mandate to become independent of foreign oil ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... mimicking a brick-and-mortar molecular structure found in seashells, University ... strong as steel but lighter and transparent. , ... water-soluble polymer that shares chemistry with white glue. , ... but the new material isn,t quite stretchy enough to ...
... with,its third quarter 2007 earnings release (expected to be issued ... ) is pleased to invite you to,listen to its quarterly ... on Thursday, October 25 at 9:00 a.m. ET. What: ... Presentation When: October 25, 2007, 9:00 a.m. ...
... Oct. 4 Coherent, Inc.,(Nasdaq: COHR ) today ... an additional NASDAQ Staff Determination letter indicating that,the Company ... set forth in Marketplace Rules 4350(e) and 4350(g) due ... during its fiscal,year ended September 30, 2007. The notice ...
Cached Biology Technology:U-M research: New plastic is strong as steel, transparent 2Coherent, Inc. Receives Expected Letter from NASDAQ 2
(Date:8/28/2014)... are healthier for your neighbors than traditional cigarettes, ... to a new study from USC. , Scientists ... 10-fold decrease in exposure to harmful particles, with ... exposure to some harmful metals in second-hand e-cigarette ... While tobacco smoke contains high levels of polycyclic ...
(Date:8/28/2014)... (August 28, 2014) Researchers at the University of ... muscular dystrophy (FSHD) to be used for muscle regeneration ... potential therapies for FSHD. , The research is published ... Reports . , There is no treatment for FSHD, ... common type of muscular dystrophy. FSHD is an unusual ...
(Date:8/28/2014)... developmental on-off switch for Streptomyces , a group ... the world,s naturally derived antibiotic medicines. , Their ... possible to manipulate this switch to make nature,s antibiotic ... 28 in Cell , found that a unique ... larger protein called BldD ultimately controls whether a bacterium ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... remains a devastating problem in Africa and understanding the ... the effort to combat the disease. A new study ... conducted in Western Kenya by Jacob Koella and colleagues ... with the infectious stages of malaria than to those ...
... warfarin to prevent harmful clotting after a heart attack, stroke, ... vary greatly and can be hard to predict. Some of ... involved in blood clotting, according to a new study published ... of Medicine. , By looking at the genetic makeup of ...
... of Utah researchers showed that a fruit fly gene ... into adults, and how the transformation initially proceeds. Understanding ... children become surly teenagers. , When the DHR4 gene ... an immature larva to a sexually active adult. It ...
Cached Biology News:Mosquitoes are more attracted to individuals infected with malaria 2Genetic variation alters response to common anti-clotting drug 2Genetic variation alters response to common anti-clotting drug 3Scientists find a maturity gene in fly 2Scientists find a maturity gene in fly 3Scientists find a maturity gene in fly 4
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
...
Mouse Amphiregulin MAb (Clone 206220)...
Biology Products: